Pacific Biosciences
PACB
274 hedge funds and large institutions have $2.86B invested in Pacific Biosciences in 2023 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 104 increasing their positions, 75 reducing their positions, and 45 closing their positions.
146% more call options, than puts
Call options by funds: $54M | Put options by funds: $22M
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
39% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 75
30% more capital invested
Capital invested by funds: $2.2B → $2.86B (+$669M)
4.8% more ownership
Funds ownership: 104.41% → 109.21% (+4.8%)
9% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 45
0% more funds holding
Funds holding: 274 → 274 (0)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$163M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$38.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.7M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$23.8M |
| 5 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$22.7M |
Top Sellers
PACB Hedge Fund Activity: Q4 2023 in Review
274 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2023, worth a combined $2.86B — up 30% from $2.2B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new PACB positions and 45 closed out — a net gain of 4 holders — while 104 added to existing stakes and 75 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $163M. The largest seller was Farallon Capital Management, cutting an estimated $33M.
- 274 institutional investors held Pacific Biosciences (PACB) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $2.86B of Pacific Biosciences stock for Q4 2023, up 30% quarter-over-quarter.
- 49 funds opened new Pacific Biosciences positions in Q4 2023 and 45 closed out, a net change of +4 holders.
- The largest Pacific Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $163M added.
- The largest Pacific Biosciences seller in Q4 2023 was Farallon Capital Management, an estimated $33M sold.
Based on aggregated 13F filings for Q4 2023.